Tag Archive for: Frontotemporal Dementia

Scenic Biotech Appoints Renowned Neurology Drug Development Leader Dr. Judith Walker as Chief Medical Officer

/in

Dr. Walker joins to lead Scenic’s transition into clinical development and shape its clinical strategy Lead program SC6177 is advancing toward the clinic with a first-in-class approach to restoring lysosomal function, a key driver of multiple neurodegenerative disease Amsterdam, The Netherlands — 10 September 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose […]

Read more

Jacob Falck Hansen appointed as Chief Executive Officer of Vesper Bio

/in

Copenhagen, Denmark, 01 July 2025 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech developing an oral therapy for frontotemporal dementia, today announces the appointment of Jacob Falck Hansen as Chief Executive Officer (CEO). Jacob Falck Hansen brings more than 15 years of leadership experience from the pharmaceutical and biotech industry. He […]

Read more

Vesper Bio achieves enrolment milestone in Phase Ib/IIa trial of lead candidate VES001 for frontotemporal dementia

/in

Phase Ib/IIa trial is to evaluate the efficacy of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia A total of six participants have been enrolled in the trial across two sites – one in the Netherlands and one in the United Kingdom Copenhagen, Denmark, 09 May 2025 – Vesper Bio ApS (“Vesper” […]

Read more

Vesper Bio initiates Phase Ib/IIa proof of concept study of VES001 in asymptomatic patients with gene mutations that cause frontotemporal dementia (FTD)

/in

Dosing of VES001 has commenced in patients with causal gene mutations for FTD(GRN), a type of frontotemporal dementia which is invariably fatal This follows Vesper having received clinical trial authorisation from the Netherlands and the United Kingdom to initiate its Phase Ib/IIa “SORT-IN-2” trial VES001 is a first-in-class, potentially disease-modifying, orally-dosed, brain-penetrant treatment for FTD(GRN), […]

Read more

Vesper Bio announces successful Phase I study for potentially disease-modifying treatment for frontotemporal dementia

/in

VES001 is a first-in-class oral, brain penetrant, small molecule sortilin inhibitor for treatment of FTD(GRN) Data demonstrate excellent safety, tolerability profile, dose-proportionality and target engagement with elevations in progranulin in both plasma and CNS CTA filed for Phase IIa study, first dose targeted for Q4 2024 Copenhagen, Denmark, 04 September 2024 – Vesper Bio ApS […]

Read more
© Optimum Strategic Communications.